In the TCGA melanoma cohort, the median overall survival (OS) for the low NEK9 expression group was 2.57 years (95% CI: 1.87, 5.68) compared to a median OS for the high NEK9 expression group of 1.98 years (95% CI: 1.27, 2.70). This evidence concerns the gene NEK9 and melanoma.